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Background. Renin has been linked to the pathogenesis of
some forms of hypertension, including cold-induced hyperten-
sion (CIH). Although several antihypertensive drugs that in-
hibit angiotensin-converting enzyme (ACE) and angiotensin II
(Ang II) type 1 (AT1) receptors are available, they are short-
lasting and have side effects. Inhibition of renin [the first and
rate-limiting step of the renin-angiotensin system (RAS)] would
provide an inhibition of the entire RAS. Thus, we developed
an antisense approach for specific inhibition of renin based on
the genetic design. The objective of this study was to test our
hypothesis that adenoviral delivery of renin antisense inhibits
renin and attenuates CIH.
Methods. Recombinant adenoviruses carrying rat renin anti-
sense (rAdv.RRA) and LacZ reporter gene (rAdv.LacZ) were
constructed and used for in vivo gene transfer via intravenous
injection. Four groups of rats were used (six rats/group). Blood
pressure did not differ among the four groups during the control
period at room temperature (25◦C). Two groups of rats received
rAdv.RRA (2.5 × 109 pfu/rat, intravenously), while the other
two groups received the same dose of rAdv.LacZ and served as
controls. After gene delivery, one rAdv.LacZ-treated and one
rAdv.RRA-treated group were exposed to cold (5◦C), while the
remaining groups were kept at 25◦C. Blood pressure was moni-
tored weekly during cold exposure. A 24-hour urine sample was
collected during weeks 1, 3, and 5 for measuring urinary aldos-
terone excretion. At the end of week 5, all animals were killed
and blood was collected for measurement of plasma renin activ-
ity (PRA), total plasma renin, plasma active renin, and plasma
aldosterone. Vascular Ang II contents were measured in all rats.
Results. Blood pressure of the rAdv.LacZ-treated group rose
significantly within 2 weeks of exposure to cold and reached
158.2 ± 6.4 mm Hg by week 5. In contrast, blood pressure
(117.1 ± 5.3 mm Hg) of the cold-exposed group treated with
rAdv.RRA did not increase until 5 weeks after exposure to
cold. Thus, a single dose of rAdv.RRA prevented CIH for at
least 5 weeks. rAdv.RRA abolished the cold-induced increases
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in PRA, total plasma renin, plasma active renin, vascular Ang
II, and plasma and urine aldosterone, indicating effective inhi-
bition of the entire RAS.
Conclusion. rAdv.RRA effectively inhibited the entire RAS
and produced prolonged attenuation of CIH. Antisense inhibi-
tion of renin may be a novel and ideal approach for long-term
control of hypertension.
The renin-angiotensin system (RAS) is essential for
fluid balance and blood pressure regulation [1, 2]. The
RAS plays an important role in the pathogenesis of some
forms of hypertension, including cold-induced hyperten-
sion (CIH). Angiotensin II (Ang II) type 1 (AT1) recep-
tor blockers and angiotensin-converting enzyme (ACE)
inhibitors have been used to treat high blood pressure in
hypertensive patients [3]. However, these available an-
tihypertensive agents are short-lasting, nonspecific, and
have side effects. In addition, blockade of AT1 receptors
or inhibition of ACE results in a reactive rise in renin
release and an excessive accumulation of angiotensin I
(Ang I), which are generally attributed to interruption of
the short feedback loop between angiotensin II (Ang II)
and renin release [4–9]. Ang I, though less potent than
Ang II, has pressor effect and can stimulate aldosterone
release, which may make hypertension difficult to control
[10]. In contrast, inhibition of renin could provide an inhi-
bition of the entire RAS. Inhibition of renin by renin an-
tibodies, synthetic derivatives of the prosegment of renin
precursor, pepstatin analogues, and angiotensinogen ana-
logues [11, 12], has been unsuccessful due to low potency,
poor bioavailability, and high costs of synthesis [2, 13].
Recently, a new nonpeptide renin inhibitor, aliskiren, was
synthesized and used for clinical trial [14]. It is noted
that aliskiren, even at a very high dose (300 mg/day),
lowers blood pressure by only 11.4 mm Hg in hyperten-
sive patients after 4 weeks of treatment. This indicates
that aliskiren may not be an efficient antihypertensive
agent. Thus, there presently is a lack of ideal pharma-
cologic agents that can effectively inhibit renin, the first
and rate-limiting component of the RAS Antisense DNA
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designed specifically against renin might be a unique
renin inhibitor. Antisense inhibition, via a number of
mechanisms [15], can effectively down-regulate the ex-
pression of target protein. The major advantage of anti-
sense approach is the specificity of antisense DNA based
on DNA sequence.
Intracerebroventricular injection of renin antisense
oligodeoxynucleotides can cause a transient decrease in
blood pressure in spontaneously hypertensive rats [16].
This is because the oligodeoxynucleotides are usually di-
gested by endonuclease and its effect lasts for only a
few days [17]. In contrast, the effect of antisense deliv-
ery based on vectors could last longer (weeks or months)
[17]. Adenovirus as a vector possess high efficiency for
gene transfer, broad species and tissue trophism, rapid
propagation of recombinant virus to high titers, simple
techniques for generation of recombinant viral genomes
[18]. Thus, adenovirus is widely used for experimental
studies although it currently has important limitations in
human gene therapy [19].
Chronic cold exposure induces hypertension in rats
within 3 weeks, namely CIH [20–25]. CIH represents a
unique high renin model of hypertension, which is in-
duced without genetic manipulation, surgical interven-
tion, or large doses of drugs or hormones. Numerous
studies suggest that the RAS plays an important role in
the initiation and development of CIH [21, 24, 26–28]. In
this study, we constructed recombinant adenovirus car-
rying an antisense DNA complementary to rat renin. We
hypothesized that adenoviral delivery of renin antisense,
through specific inhibition of renin, attenuates the devel-
opment of CIH.
METHODS
Construction of recombinant adenovirus with rat
renin antisense (rAdv.RRA)
Total RNA extracted from rat kidney (Sprague-
Dawley strain) was used for synthesizing the rat renin
cDNA (747 bp) by reverse transcription-polymerase
chain reaction (RT-PCR) for 35 cycles, with annealing
at 58.5◦C. Primers for rat renin were designed by using
Primer Premier 5.0 according to the published rat renin
sequence [29]. The rat renin specific primers are 5′-CCAC
CTTAAG CTC AAG AAA ATG CCC TCG GTC-3′
(forward) and 5′-CAAC TCTAGA CA GCC CTC CTC
ACA CAA CAA G-3′ (reverse).
rAdv.RRA or rAdv.LacZ driven by cytomegalovirus
(CMV) promoter was constructed using an Adeno-X-
DNA system (BD Biosciences Clontech, Palo Alto, CA,
USA) according to the manufacturer’s instruction. The
recombinant Adeno-X-DNA-Renin (prAdv.RRA) plas-
mid was identified by PCR using Adeno-XTM PCR
primers set two (BD Biosciences Clontech) and rat
renin specific primers (forward 5′-CTCAAGAAAAT
GCCCTCGGTC-3′, reverse 5′-CAGCCCTCCTCACAC
AACAAG-3′). The rAdv.RRA and rAdv.LacZ were am-
plified and purified and the final titers were determined
as described recently [30].
Animal study protocols
Four groups (six rats/group) of Sprague-Dawley rats
(200 to 220 g) were used. Systolic blood pressure and body
weight was measured one time during the control period
at room temperature (25◦C). Systolic blood pressure was
measured from the tail of each unanesthetized rat by the
tail-cuff method with slight warming (28◦C) but not heat-
ing of the tail as described previously [21, 23, 26]. All rats
were handled frequently (three times/day) to minimize
handling stress. Animals do not appear stressed during
blood pressure measurement. The tail-cuff method has
been used by us [21, 23, 26, 31] and others [20, 24, 32, 33]
to delineate cold-induced elevation of blood pressure. It
has been confirmed, by the intra-arterial cannulation, that
the noninvasive tail-cuff method is effective and reliable
in monitoring systolic blood pressure in rats chronically
exposed to cold [25].
After the control period, two groups of rats re-
ceived intravenous administration of rAdv.RRA (2.5 ×
109 pfu/rat) (0.5 mL) under light anesthesia (sodium
pentobarbital, 50 mg/kg, intraperitoneally). The other
two groups received same bolus of rAdv.LacZ (2.5 ×
109 pfu/rat) and served as controls. After recovery,
one Adv.RRA-treated group and one Adv.LacZ-treated
group were moved into a cold climate–controlled walk-
in chamber (6.7 ± 2◦C), while the remaining groups were
kept in an identical warm chamber (room temperature,
25 ± 2◦C). Relative humidity was controlled automati-
cally at 45 ± 5%. Blood pressure and body weight were
measured weekly during exposure to cold. During weeks
1, 3, and 5, a 24-hour urine sample was collected for mea-
surement of urinary excretion of aldosterone. At the end
of week 5 of exposure to cold, all animals were killed by
decapitation and blood was collected in chilled tubes con-
taining ethylenediaminetetraacetic acid (EDTA). Plasma
was separated by centrifugation and saved at −80◦C
for determination of plasma renin activity (PRA), total
plasma renin concentration, plasma active renin concen-
tration, and plasma aldosterone level. Aorta and small
(mesenteric and tail) arteries were saved for measure-
ment of vascular Ang II contents. No visible inflamma-
tion was found in heart, blood vessels, lungs, kidneys, and
liver during autopsy.
PRA
PRA was assayed by using a radioimmunoassay (RIA)
kit (PerkinElmer Life Sciences, Boston, MA, USA) as
described in our previous studies [26, 31]. Total plasma
renin (active renin and prorenin) and plasma active renin
were measured by RIA, using monoclonal antibodies that
react with both renin and prorenin and antibodies that
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only recognize active renin as described by Derkx et al
[34].
Plasma and urine aldosterone
Plasma aldosterone concentrations were measured
with a RIA kit (Coat-a-Count) (Diagnostic Products Cor-
poration, Los Angeles, CA, USA) according to the man-
ufacturer’s instruction. Plasma (60 lL) was incubated for
3 hours at 37◦C in the presence of a specific aldosterone
antibody and 125I-aldosterone and quantified on a gamma
counter.
Urine was acidified by the addition of 3.2 N HCl and
incubated for 24 hours at room temperature in the dark.
The acidified solution was then extracted with ethyl ac-
etate. After centrifugation, 100 lL of the supernatant was
transferred to a new tube and evaporated to complete
dryness. The extract was then diluted with 0.5 mL of the
zero-matrix diluent provided with the aldosterone assay
kit. The RIA procedure used for plasma aldosterone was
then employed.
Vascular Ang II
Aorta and small arteries (mesenteric and tail) were ho-
mogenized for Ang II assay. Vascular tissue contents of
Ang II were measured by RIA as described in our previ-
ous study [31]. The Ang II RIA is sensitive to 1 pg/tube.
X-gal staining of LacZ
LacZ reporter gene expression in mesenteric arteries
was visualized by using X-gal staining as described by van
Tuyl et al [35].
Statistical analysis
The data for blood pressure, body weight, and urine
aldosterone excretion were analyzed by a three-way
analysis of variance (ANOVA) (main factors tempera-
ture, time, and treatment), followed by two- or one-way
ANOVA. PRA, plasma renin concentrations, plasma al-
dosterone levels, and vascular Ang II contents were ana-
lyzed by a two-way ANOVA (main factors temperature
and treatment), followed by a one-way ANOVA. The
Newman-Keuls procedure was used to assess the signifi-
cance of differences between means. The significance was
set at 95% CI.
RESULTS
rAdv.RRA
The recombinant pAdv.RRA contained rat renin an-
tisense (747 bp) and adeno-X backbone sequences (312
bp) (Fig. 1).
Blood pressure
Systolic blood pressure did not differ significantly
among the four groups during the control period at room
312 bp
1 2 3 4 5 6 7 8 9 10
747 bp
1 2 3 4 5 6 7 8 9 10
A
B
Fig. 1. Identification of recombinant adenovirus with rat renin anti-
sense (prAdv.RRA) by polymerase chain reaction (PCR). (A) Lanes
1 to 8 show 312 bp products, eight plasmids from eight colonies of Es-
cherichia coli as the templates and Adeno-XTM PCR primers set two as
primers. Lane 9 shows 312 bp DNA fragment as a positive control. Lane
10 shows 1 kb DNA ladder. (B) Lanes 1 to 8 show 747 bp products, eight
plasmids (the same as the above) as the templates and rat renin-specific
primers as primers. Lane 9 shows 1 kb DNA ladder. Lane 10 shows 747
bp DNA fragment as a positive control.
temperature (Fig. 2). Blood pressure of the rAdv.LacZ-
treated group increased significantly (P < 0.01) within
2 weeks of exposure to cold. Blood pressure of this group
continued to increase thereafter and reached a peak level
at week 5 (158.2 ± 6.4 mm Hg) (Fig. 2). The repeated mea-
sures ANOVA revealed a significant (P < 0.001) treat-
ment × temperature interaction (F = 3.68). In contrast,
blood pressure of the cold-exposed rAdv.RRA-treated
group did not increase until 5 weeks after exposure to
cold (117.1 ± 5.3 mm Hg).
Body weights of the four groups did not differ signifi-
cantly from each other throughout the experiment (data
not shown).
PRA
PRA (Fig. 3A), plasma active renin concentration
(Fig. 3B), and total plasma renin concentration (Fig. 3C)
were significantly higher in the Adv.LacZ-cold group
than in the Adv.RRA-cold group. This indicates that
rAdv.RRA blocked the cold-induced increase in PRA
and plasma renin concentrations. rAdv.RRA did not af-
fect these parameters in rats kept in warm (room temper-
ature, 25◦C).
Vascular Ang II
Ang II levels in aorta and small arteries were signif-
icantly higher in the Adv.LacZ-cold group than in the





























Fig. 2. Effect of adenoviral delivery of rat
renin antisense on cold-induced elevation of
blood pressure (mean ± SEM). Intravenous
injections of recombinant adenovirus with
rat renin antisense (rAdv.RRA) or recom-
binant adenovirus with LacZ (rAdv.LacZ)
were carried out immediately before ex-
posure to cold. Adv.LacZ-Cold are rats
treated with rAdv.LacZ and exposed to
cold; Adv.RRA-Cold are rats treated with
rAdv.RRA and exposed to cold; Adv.RRA-
Warm are rats treated with rAdv.RRA and
kept at room temperature; Adv.LacZ-Warm
are rats treated with rAdv.LacZ and kept at


































































































Fig. 3. Effect of adenoviral delivery of rat
renin antisense on plasma renin activity
(PRA) (A), plasma active renin concentra-
tion (B), and total plasma renin concentra-
tion (C) (mean ± SEM). These were mea-
sured when animals were sacrificed at 5
weeks after gene delivery. Adv.LacZ-Cold are
rats treated with rAdv.LacZ and exposed to
cold; Adv.RRA-Cold are rats treated with
rAdv.RRA and exposed to cold; Adv.RRA-
Warm are rats treated with rAdv.RRA and
kept at room temperature; Adv.LacZ-Warm
are rats treated with rAdv.LacZ and kept at
room temperature. ∗∗P < 0.001, compared
with the LacZ-Warm group; ++P <0.001 com-
pared with the LacZ-Cold group (N = 6).
Adv.RRA-cold group (Table 1). rAdv.RRA blocked the
cold-induced increase in vascular Ang II concentration.
rAdv.RRA did not affect vascular Ang II levels in rats
kept in warm (25◦C).
Plasma and urine aldosterone
Chronic cold exposure significantly increased plasma
aldosterone concentration in the rAdv.LacZ-treated rats
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Table 1. Effect of adenoviral delivery of renin antisense on vascular
contents of angiotensin II (Ang II) (pg/mg protein)
Group Aorta Small Arteries
Adv.LacZ-cold 159.3 ± 11.8a 164.7 ± 12.4a
Adv.RRA-cold 123.3 ± 10.6b 128.0 ± 11.6b
Adv.RRA-warm 117.7 ± 11.2b 121.9 ± 13.2b
Adv.LacZ-warm 123.8 ± 10.8b 128.5 ± 12.1b
Measurement was done at 5 weeks after gene delivery (n = 6 rats/group).
aP < 0.001 compared with the Adv.LacZ-warm group;bP < 0.001 compared
with the Adv.LacZ-cold group.
(Fig. 4A). rAdv.RRA blocked the cold-induced increase
in plasma aldosterone concentration. rAdv.RRA did not
affect plasma aldosterone concentration in rats kept in
warm (25◦C).
Chronic cold exposure significantly increased urinary
aldosterone excretion during weeks 1, 3, and 5. Because
similar changes were found at all of the three time points,
only data from week 3 are shown (Fig. 4B). rAdv.RRA
blocked the cold-induced increase in urinary aldosterone
excretion. rAdv.RRA partially decreased urinary aldos-
terone excretion in rats kept in warm temperature. This
decrease, however, was not significant.
X-gal staining of in vivo LacZ expression
X-gal staining showed that LacZ reporter gene ex-
pressed in mesenteric arteries (Fig. 5) of rats treated with
rAdv.LacZ at 5 weeks after gene delivery. No X-gal stain-
ing was found in mesenteric arteries of rats treated with
rAdv.RRA, indicating absence of LacZ gene expression.
DISCUSSION
The present study clearly demonstrated that adenovi-
ral delivery of rat renin antisense prevented the devel-
opment of CIH (Fig. 2). An intravenous injection of
rAdv.RRA significantly attenuated cold-induced eleva-
tion of blood pressure for up to 5 weeks (length of the
study). The prolonged attenuation of hypertension is im-
portant because it may open a new avenue for the long-
term control of hypertension by specific inhibition of
renin. This new approach may have advantages over the
pharmacologic antihypertensive drugs (losartan, capto-
pril, b blockers, etc.) which are not highly specific, short-
lasting (<24 hours), and associated with side effects. At
a very high dose (300 mg/day), the new pharmacologic
renin inhibitor aliskiren dropped blood pressure by only
11.4 mm Hg in hypertensive patients after a 4-week treat-
ment [14]. In addition to its low potency, aliskiren has a
short duration of action and daily doses are required [14].
In contrast, a single dose of rAdv.RRA kept the blood
pressure of the cold-exposed rats at the control level for
at least 5 weeks (Fig. 2). A further study is required to de-
termine the effect of rAdv.RRA on established CIH or
established Ang II/aldosterone excess with parallel com-
parisons with the antihypertensive effects of aliskiren, an
ACE inhibitor, and an AT1 receptor blocker.
Renin was successfully inhibited by adenoviral delivery
of renin antisense as evidenced by significant reductions
in PRA (Fig. 3A), plasma active renin (Fig. 3B), and total
plasma renin (Fig. 3C). It is important that Ang I forma-
tion (Fig. 3A), vascular Ang II contents (Table 1), and
plasma aldosterone levels (Fig. 4A) were also decreased
by rAdv.RRA in the cold-exposed rats. These results
suggest that the entire RAS was inhibited by systemic
delivery of rAdv.RRA in the cold-exposed rats. Thus,
inhibition of renin, the initial component of the RAS
overcomes the limitations of currently available AT1 re-
ceptor blockers and ACE inhibitors which only partially
block the RAS. Blockade of AT1 receptors or inhibition
of ACE can result in a reactive rise in renin release and an
excessive accumulation of Ang I (4–9), which may make
hypertension difficult to control [10]. Renin inhibitors
such as aliskiren were designed to antagonize renin activ-
ity based on similar structure [36]. Thus, treatment with a
renin inhibitor increases plasma concentrations of active
and total renin, although suppressing PRA [37, 38]. In
sharp contrast, antisense inhibition of renin suppressed
both PRA (Fig. 3A) and renin production (Fig. 3B and
C). rAdv.RRA inhibition of Ang II generation (Table 1)
is superior to that of ACE inhibitors which result in accu-
mulation of other peptides like substance P or bradykinin
and therefore cause unwanted drug effects like cough and
angioedema.
Renin is an aspartyl protease and plasma renin is
mainly secreted by juxtaglomerular cell of the kidneys.
Although it was suggested that measurement of PRA
is a good method to detect plasma renin protein level
[39, 40], we measured both PRA and plasma renin pro-
tein levels in the present study to more reliably evaluate
the renin production. Cold-induced increases in the en-
zymatic activity of renin were abolished by rAdv.RRA
(Fig. 3A). This is likely due to inhibited renin formation
as evidenced by decreased plasma renin protein levels
in cold-exposed rats treated with rAdv.RRA (Fig. 3B).
These results suggest an effective inhibition of renin pro-
tein synthesis by rAdv.RRA. It is interesting to note
that rAdv.RRA inhibited cold-stimulated renin forma-
tion and kept it at the control level, but did not affect
renin secretion under normal conditions. The mechanism
of the selective inhibition is still under investigation, but
it seems that the cold-activated renin-secreting cells are
more sensitive to antisense inhibition. This finding is im-
portant because renin antisense not only down-regulates
stress-induced renin release but allow normal physiology
of the RAS as well. This feature is ideal for appropriate
control of hypertension.
Recombinant Adv.RRA was successfully constructed
as it contained both the therapeutic gene (renin


































































Fig. 4. Effect of adenoviral delivery of rat
renin antisense on plasma aldosterone con-
centration (A) and urinary aldosterone excre-
tion (B) (mean ± SEM). Plasma aldosterone
concentration was measured when animals
were sacrificed at 5 weeks after gene delivery.
Urinary aldosterone excretion was measured
during week 3 post-gene delivery. Adv.LacZ-
Cold are rats treated with rAdv.LacZ and
exposed to cold; Adv.RRA-Cold are rats
treated with rAdv.RRA and exposed to
cold; Adv.RRA-Warm are rats treated with
rAdv.RRA and kept at room tempera-
ture; Adv.LacZ-Warm are rats treated with
rAdv.LacZ and kept at room temperature.
∗∗P < 0.001, compared with the LacZ-Warm
group; ++P < 0.001 compared with the LacZ-
Cold group (N = 6).
Adv.LacZ-Cold Adv.RRA-Cold
Fig. 5. X-gal staining of LacZ in superior mesenteric arteries. X-gal staining was carried out when animals were sacrificed at 5 weeks after gene
delivery. Left, X-gal staining of LacZ in a mesenteric artery from a rat treated with recombinant adenovirus with LacZ (rAdv.LacZ). Arrows
indicate the LacZ expression (blue staining) in a mesenteric artery. Right, negative X-gal staining in a mesenteric artery from a rat treated with
recombinant adenovirus with rat renin antisense (rAdv.RRA), indicating no LacZ expression (original magnification ×10).
antisense) and adenoviral backbone (Fig. 1). The in vivo
gene transfer was efficient as evidenced by successful in-
hibition of PRA and renin production (Fig. 3). It was
reported that intracerebroventricular injection of renin
antisense oligodeoxynucleotides caused a rapid and tran-
sient (<3 days) decrease in blood pressure in sponta-
neously hypertensive rats [16]. In contrast, adenoviral
delivery of renin antisense is more efficient because it
produced greater and longer-lasting antihypertensive ef-
fect (Fig. 2). Adenovirus has many advantages for di-
rect introduction of the foreign genes into mammalian
cells, and possesses the high efficiency of gene trans-
fer, broad species and tissue trophism, rapid propaga-
tion of recombinant virus to high titers, and simple tech-
niques for generation of recombinant viral genomes [41].
It was reported that the in vivo adenoviral-mediated
gene transfer reached a peak level by 2 weeks and de-
creased to a minimal level by 4 weeks [42]. However, a
single intravenous injection of recombinant adenovirus
with human kallikrein gene decreased blood pressure for
24 days in Goldblatt hypertensive rats [43]. The present
study clearly demonstrated that the inhibitory effect of
rAdv.RRA on blood pressure, PRA, and plasma renin
protein still existed at 5 weeks after gene delivery (Figs. 2
and 3). X-gal staining indicates that LacZ reporter gene
delivered by adenovirus also existed in the mesenteric
artery at 5 weeks after gene delivery (Fig. 5). These re-
sults indicate that the in vivo adenoviral-mediated gene
delivery was successful.
The extensive portions of the early regions 1 (E1)
and 3 (E3) of wild-type adenovirus had been deleted
from the adenovirus type 5 genome (Adv5) [44, 45]. No
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cytopathic efficiency (CPE) occurred in human ab-
dominal aortic endothelial cells (HAAE1) and rat
heart cells (H9c2) transfected with rAdv5 even at a
high titer [multiplicity of infection (MOI) of 200] be-
cause these cells lack the necessary transcription fac-
tors (E1 genes) [30]. Thus, the adenoviral vector (Adv5)
we used provides valuable safety feature. In fact, no
visible inflammation was found during tissue collec-
tion. Although adenovirus has advantages for exper-
imental gene transfer, it is largely limited to deliver
recombinant DNA to humans due to its failure to inte-
grate transgene into the host genomes and its potential
inflammatory effect in humans [19]. Compared with AAV
or lentivirus, adenovirus-mediated transgene has rela-
tively short-lasting effect (weeks). It is highly likely that
repeated administrations of rAdv.RRA may decrease
its efficacy and cause immune responses. In addition,
rAdv.RRA lacks effective regulatory mechanism for ad-
justing the therapeutic gene expression according to the
treatment need. Therefore, a stable and nonpathogenic
vector preferably engineered with a regulatory system
should be used to deliver renin antisense to humans for
antihypertensive therapy.
CONCLUSION
The present study showed that adenoviral delivery of
renin antisense was effective in prevention of CIH. A sin-
gle dose of rAdv.RRA can inhibit renin and control hy-
pertension for at least 5 weeks. Renin antisense has high
specificity because it is based on DNA sequence. Further-
more, renin has high specificity for only one substrate, an-
giotensinogen [2]. Thus, few side effects are expected with
renin antisense treatment. Therefore, renin antisense has
advantages over the currently used pharmacologic agents
(AT1 receptor blockers and ACE inhibitors) in both spe-
cific inhibition of the RAS and prolonged blood pressure
reduction. In addition, antisense inhibition of renin, the
initial and rate-limiting step of the RAS may also offer
a significant improvement over the antisense inhibition
of AT1 receptors [46, 47] in control of the entire RAS. It
should be mentioned that the adenovirus has important
limitations in human gene therapy [19]. For safe and long-
term control of hypertension, a tissue-specific promoter
and a stable vector that can integrate the therapeutic gene
into the host genome should be employed (i.e., lentivirus
or AAV) [15, 46–48].
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